Company: IMNN
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022120
Chunk: 41

Company: Imunon, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 8
Chunk 41
---
(42.3)%
  
    General and administrative expenses 
     1,577  
     1,668  
     (91) 
     (5.5)%
  
    Total operating expenses 
     3,476  
     4,961  
     (1,485) 
     (29.9)%
  
    Loss from operations 
    $(3,476) 
    $(4,961) 
    $(1,485) 
     (29.9)%

Research
and Development Expenses

Research
and development (“R&D”) expenses were $1.9 million in the third quarter of 2025 compared to $3.3 million in same period
of 2024. Clinical costs associated with the OVATION 2 and MRD trials were $0.1 million in the third quarter of 2025 compared to $0.4
million in the same period of 2024. Clinical costs associated with the OVATION 3 trial were $0.4 million in the third quarter of 2025.
Clinical costs associated with the PlaCCine vaccine trial were $9,000 in the third quarter of 2025 compared to $0.5 million in the third
quarter of 2024. Other clinical and regulatory costs were $0.4 million in the third quarter of 2025 compared to $0.8 million in the same
period of 2024. R&D costs associated with the development of IMNN-001 to support the OVATION program were $0.7 million in the third
quarter of 2025 compared to $0.2 million in same period of 2024. The cost of development of the PLACCINE DNA vaccine technology platform
was $0.6 million in the third quarter of 2024. CMC costs were $0.2 million in the third quarter of 2025 compared to $0.8 million in the
same period of 2024.

29

General
and Administrative Expenses

General
and administrative expenses were $1.6 million in the third quarter of 2025 compared to $1.7 million in the same period of 2024. The decrease
was primarily attributable to lower employee-related expenses of $0.1 million.

Investment
income from the Company’s short-term investments was $47,000 for the third quarter of 2025 compared to $116,000 for the same period
in